Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-29

FDA Approved: NORTREL 7/7/7 (28 DAY REGIMEN) — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Nortrel 7/7/7 (28-day regimen), a combined oral contraceptive containing norethindrone and ethinyl estradiol, ma…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NORTREL 7/7/7 (28 DAY REGIMEN) (NORETHINDRONE AND ETHINYL ESTRADIOL)

Snippet

SUPPL AP for NORTREL 7/7/7 (28 DAY REGIMEN) (NORETHINDRONE AND ETHINYL ESTRADIOL)